AirSculpt Q2 revenue falls more than expected
AIRS•Analyst coverage and valuation
The current average analyst rating on the shares is hold, with a breakdown of 1 strong buy or buy, 2 hold, and no sell or strong sell recommendations.
The average consensus recommendation for the healthcare facilities and services peer group is buy.
Wall Street's median 12-month price target for AirSculpt Technologies Inc is $6.25, about 24.8% above its August 7 closing price of $5.01.
Business and marketing drivers
AirSculpt said it introduced new services during the quarter, including an exclusive partnership with AlloClae to expand its treatment offering.
The company also increased brand marketing efforts during the quarter.
Quarterly results miss estimates
US body contouring provider AirSculpt said second-quarter revenue fell 3% and missed analyst expectations. Adjusted EBITDA for the quarter also declined year over year.
The company said same-center sales were stable and same-center case volume increased 1.0% in Q2.
